|
|
News for Healthier Living
Phase 2 BESTOW Trial Generates Promising Kidney Function and Quality of Life Results for Tegoprubart Versus Tacrolimus Immunosuppression in Kidney Transplant Recipients
The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.
October 23, 2026
October 30 2026October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026October 18 2026October 17 2026October 16 2026
|
|
|
|
|